In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Health insurers no longer completely cover two breast cancer drugs for women with metastasised hormone receptive breast ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly integrating cutting-edge international research with Chinese ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

"We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on ...

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and ...

Arvinas Inc (ARVN) reports significant revenue growth and a robust cash reserve, while navigating competitive pressures and ...

CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this ...